Prawo i regulacje · 30/09/2022

Daridorexant Classified as Schedule IV Substance Under Controlled Substances Act

The Drug Enforcement Administration has finalized a rule placing daridorexant, a medication used to treat sleep disorders, in Schedule IV of the Controlled Substances Act, following an interim rule published in 2022. This decision maintains daridorexant's current classification under the CSA.